Medicare AdvantagePrior AuthMedium impact
MA08.088d, Ocrelizumab (Ocrevus®) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo™)
Independence Blue Cross·Neurology, Oncology, Pharmacy·Pharmacy
Effective date
Apr 21, 2025
We identified it
Jun 19, 2026
Summary
Policy MA08.088d updates medical necessity criteria for Ocrelizumab (Ocrevus®) and Ocrelizumab and Hyaluronidase-ocsq (Ocrevus Zunovo™). This recent change (effective 04/21/2025) affects coverage requirements and prior authorization standards for these disease-modifying therapies used in multiple sclerosis treatment. Billing teams must verify current medical necessity documentation requirements before processing claims.
Action Required
By 04/21/2025: Billing and clinical teams must review the full policy text at the provided URL to identify specific medical necessity criteria updates for Ocrelizumab products. Determine if prior authorization requirements have changed and update billing system rules accordingly. Clinical staff should review updated documentation requirements and ensure provider templates capture necessary clinical information. Contact the payer (IBX Medicare Advantage) directly if criteria details are unclear from the policy summary provided. Claims submitted without current medical necessity documentation per the updated policy may be denied.